Novo Nordisk Faces Lawsuits Over Weight Loss Drug Ozempic

Plaintiffs claim the drug caused them to develop gastroparesis, leading to severe bowel injuries and lifelong diarrhea.

A woman and nearly a dozen others have filed lawsuits against Novo Nordisk, the parent company of weight loss drug Ozempic, claiming the drug caused them to develop gastroparesis, a condition that affects the movement of the stomach muscles.
The woman, who remains unidentified, had to undergo an eight-hour operation to repair her colon and was told she would suffer from diarrhea for the rest of her life.
The lawsuits claim that Novo Nordisk failed to adequately warn users about the risk of gastroparesis on the drug's packaging.
One of the plaintiffs, Brea Hand, was diagnosed with gastroparesis after using Ozempic for weight loss and to treat pre-diabetes, and has urged the company to be more transparent about the drug's risks.
It remains unclear whether the unidentified woman was using Ozempic for weight loss or for the treatment of diabetes.